The Effects of GLP1 Aagonists on Addiction

GLP1 agonists like semagluetide might short circuit the association between nicotine and food. In 2022, a research group completed the largest trial in humans so far using exenitide,. The researchers found that people with alcohol use disorder who tookExenitide had less activity in the brain's reward centers when they were shown pictures of alcohol. But only study participants with obesity ended up drinking significantly less than their peers who received a placebo.